

145. Oestergaard S, Møldrup C. Optimal duration of combined psychotherapy and pharmacotherapy for patients with moderate and severe depression: a meta-analysis. *J Affect Disord* 2011;131:24-36.
146. Mackin RS, Arean PA. Evidence-based psychotherapeutic interventions for geriatric depression. *Psychiatr Clin North Am* 2005;28(4):805-20
147. Cape John, Whittington Craig, Buszewicz Marta, Wallace Paul, Underwood Lisa. Brief psychological therapies for anxiety and depression in primary care: meta-analysis and meta-regression *BMC Medicine* 2010, 8:38.
148. de Maat S, Dekker J, Schoevers R, van Aalst G, Gijsbers-van Wilk C, Hendriksen M, Kool S, Peen J, Van R, de Jonghe F: Short psychodynamic supportive psychotherapy, antidepressants, and their combination in the treatment of major depression: a mega-analysis based on three randomized clinical trials. *Depress Anxiety* 2008; 25:565–574.
149. Pampallona S, Bollini P, Tibaldi G, Kupelnick B, Munizza C: Combined pharmacotherapy and psychological treatment for depression: a systematic review. *Arch Gen Psychiatry* 2004; 61:714–719.
150. Schramm E, van Calker D, Dykieriek P, Lieb K, Kech S, Zobel I, Leonhart R, Berger M: An intensive treatment program of interpersonal psychotherapy plus pharmacotherapy for depressed inpatients: acute and long-term results. *Am J Psychiatry* 2007; 164:768–777.
151. Thase ME, Greenhouse JB, Frank E, Reynolds CF III, Pilkonis PA, Hurley K, Grochocinski V, Kupfer DJ: Treatment of major depression with psychotherapy or psychotherapy-pharmacotherapy combinations. *Arch Gen Psychiatry* 1997; 54:1009–1015.
152. Keller MB, McCullough JP, Klein DN, Arnow B, Dunner DL, Gelenberg AJ, Markowitz JC, Nemeroff CB, Russell JM, Thase ME, Trivedi MH, Zajecka J: A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression. *N Engl J Med* 2000; 342:1462–1470.
153. [Simon GE](#), [Savarino J](#), [Operskalski B](#), [Wang PS](#) Suicide risk during antidepressant treatment. [Am J Psychiatry](#). 2006 Jan;163(1):41.
154. American Psychiatric Association: Practice Guideline for the Assessment and Treatment of Patients With Suicidal Behaviors. *Am J Psychiatry* 2003; 160(Nov suppl):1–60.
155. Wohlfarth TD, van Zwieten BJ, Lekkerkerker FJ, Gispen-de Wied CC, Ruis JR, Elferink AJ, Storosum JG: Antidepressants use in children and adolescents and the risk of suicide. *Eur Neuropsychopharmacol* 2006; 16:79–83
156. Kaizar EE, Greenhouse JB, Seltman H, Kelleher K: Do antidepressants cause suicidality in children? A Bayesian meta-analysis. *Clin Trials* 2006; 3:73–90.
157. Dubicka B, Hadley S, Roberts C: Suicidal behaviour in youths with depression treated with new-generation antidepressants: meta-analysis. *Br J Psychiatry* 2006; 189:393–398.



Με την συγχρηματοδότηση  
της Ελλάδας και της  
Ευρωπαϊκής Ένωσης



www.espa.gr

[www.ygeia-pronoia.gr](http://www.ygeia-pronoia.gr)

158. Bridge JA, Iyengar S, Salary CB, Barbe RP, Birmaher B, Pincus HA, Ren L, Brent DA: Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials. *JAMA* 2007; 297:1683–1696
159. Hammad TA, Laughren T, Racoosin J: Suicidality in pediatric patients treated with antidepressant drugs. *Arch Gen Psychiatry* 2006; 63:332–339.
160. Hammad TA, Laughren TP, Racoosin JA: Suicide rates in short-term randomized controlled trials of newer antidepressants. *J Clin Psychopharmacol* 2006; 26:203–207.
161. Akiskal HS, Benazzi F, Perugi G, Rihmer Z: Agitated "unipolar" depression re-conceptualized as a depressive mixed state: implications for the antidepressant-suicide controversy. *J Affect Disord* 2005, 85(3):245-258.
162. Rihmer Z, Akiskal H: Do antidepressants t(h)reat(en) depressives? Toward a clinically judicious formulation of the antidepressant- suicidality FDA advisory in light of declining national suicide statistics from many countries. *J Affect Disord* 2006, 94:3-13.
163. Rihmer Z: Suicide risk in mood disorders. *Curr Opin Psychiatry* 2007, 20(1):1722.
164. Sokero TP, Melartin TK, Rytsala HJ, Leskela US, Lestela-Mielonen PS, Isometsa ET: Prospective study of risk factors for attempted suicide among patients with DSM-IV major depressive disorder. *Br J Psychiatry* 2005, 186:314-318.
165. Rihmer Z: Suicide risk in mood disorders. *Curr Opin Psychiatry* 2007, 20(1):1722.
166. Kessing LV: Severity of depressive episodes according to ICD- 10: prediction of risk of relapse and suicide. *Br J Psychiatry* 2004, 184:153-156.
167. Sokero P, Eerola M, Rytsala H, Melartin T, Leskela U, Lestela-Mielonen P, Isometsa E: Decline in suicidal ideation among patients with MDD is preceded by decline in depression and hopelessness. *J Affect Disord* 2006, 95(1-3):95-102.
168. Angst J. Clinical course of affective disorders. In: Helgason T, Daly RJ, editors. *Depression illness: predication of course and outcome*. Berlin: Springer-Verlag; 1988. p. 1–47.
169. Allen NB, Hetrick SE, Simmons JG, et al. Early intervention for depressive disorders in young people: the opportunity and the (lack of) evidence. *Med J Aust* 2007;187(7):S15–S7.



Με την συγχρηματοδότηση  
της Ελλάδας και της  
Ευρωπαϊκής Ένωσης



[www.ygeia-pronoia.gr](http://www.ygeia-pronoia.gr)

170. Lam RW, Kennedy SH. Evidence-based strategies for achieving and sustaining full remission in depression: focus on metaanalyses. *Can J Psychiatry* 2004;49(3 Suppl 1):175–265.
171. Rush AJ, Kraemer HC, Sackeim HA, Fava M, Trivedi MH, Frank E, Ninan PT, Thase ME, Gelenberg AJ, Kupfer DJ, Regier DA, Rosenbaum JF, Ray O, Schatzberg AF: Report by the ACNP Task Force on response and remission in major depressive disorder. *Neuropsychopharmacology* 2006; 31:1841–1853.
172. Agency for Healthcare Policy Research: Evidence Report on Treatment of Depression—Newer Pharmacotherapies. San Antonio Evidence-Based Practice Center. Washington, DC, AHCP, Evidence-Based Practice Centers, 1999.
173. Rush AJ. Strategies and tactics in the management of maintenance treatment for depressed patients. *J Clin Psychiatry* 1999;60:21-26.
174. Judd LL, Paulus MJ, Schettler PJ, Akiskal HS, Endicott J, Leon AC, Maser JD, Mueller T, Solomon DA, Keller MB: Does incomplete recovery from first lifetime major depressive episode herald a chronic course of illness? *Am J Psychiatry* 2000; 157:1501–1504.
175. McGrath PJ, Stewart JW, Petkova E, Quitkin FM, Amsterdam JD, Fawcett J, Reimherr FW, Rosenbaum JF, Beasley CM Jr: Predictors of relapse during fluoxetine continuation or maintenance treatment of major depression. *J Clin Psychiatry* 2000; 61:518–524.
176. Solomon DA, Keller MB, Leon AC, Mueller TI, Lavori PW, Shea MT, Coryell W, Warshaw M, Turvey C, Maser JD, Endicott J: Multiple recurrences of major depressive disorder. *Am J Psychiatry* 2000; 157:229–233.
177. Tew JD Jr, Mulsant BH, Haskett RF, Joan P, Begley AE, Sackeim HA: Relapse during continuation pharmacotherapy after acute response to ECT: a comparison of usual care versus protocolized treatment. *Ann Clin Psychiatry* 2007; 19:1–4.
178. Koran LM, Gelenberg AJ, Kornstein SG, Howland RH, Friedman RA, DeBattista C, Klein D, Kocsis JH, Schatzberg AF, Thase ME, Rush AJ, Hirschfeld RM, LaVange LM, Keller MB: Sertraline versus imipramine to prevent relapse in chronic depression. *J Affect Disord* 2001; 65:27–36.
179. Judd LL, Akiskal HS, Maser JD, Zeller PJ, Endicott J, Coryell W, Paulus MP, Kunovac JL, Leon AC, Mueller TI, Rice JA, Keller MB: Major depressive disorder: a prospective study of residual subthreshold depressive symptoms as predictor of rapid relapse. *J Affect Disord* 1998; 50:97–108.
180. Fava M, Kaji J: Continuation and maintenance treatments of major depressive disorder. *Psychiatr Annals* 1994; 24:281–290.



Με την συγχρηματοδότηση  
της Ελλάδας και της  
Ευρωπαϊκής Ένωσης



[www.ygeia-pronoia.gr](http://www.ygeia-pronoia.gr)

181. Fava GA, Rafanelli C, Grandi S, Conti S, Belluardo P: Prevention of recurrent depression with cognitive behavioral therapy: preliminary findings. *Arch Gen Psychiatry* 1998; 55:816–820.
182. Jarrett RB, Basco MR, Risser R, Ramanan J, Marwill M, Kraft D, Rush AJ: Is there a role for continuation phase cognitive therapy for depressed outpatients? *J Consult Clin Psychol* 1998; 66:1036– 1040.
183. Segal ZV, Bieling P, Young T, et al. Antidepressant monotherapy vs sequential pharmacotherapy and mindfulness-based cognitive therapy, or placebo, for relapse prophylaxis in recurrent depression. *Arch Gen Psychiatry* 2010;67:1256-64.
184. Dobson KS, Hollon SD, Dimidjian S, et al. Randomized trial of behavioral activation, cognitive therapy, and antidepressant medication in the prevention of relapse and recurrence in major depression. *J Consult Clin Psychol* 2008;76:468-77.
185. Trivedi MH. Tools and strategies for ongoing assessment of depression: a measurement-based approach to remission. *J Clin Psychiatry* 2009;70:26-31.
186. Flint AJ, Rifat SL. Maintenance treatment for recurrent depression in late life. *Am J of Geriatr Psychiatry* 2000;8:2.
187. Burcusa SL, Iacono WG: Risk for recurrence in depression. *Clin Psychol Rev* 2007; 27:959–985.
188. Oxman TE, Dietrich AJ, Williams JW Jr, Kroenke K. A three-component model for reengineering systems for the treatment of depression in primary care. *Psychosomatics* 2002;43:441-50
189. Trivedi MH, Rush AJ, Gaynes BN, Stewart JW, Wisniewski SR, Warden D, Ritz L, Luther JF, Stegman D, Deveaugh-Geiss J, Howland R: Maximizing the adequacy of medication treatment in controlled trials and clinical practice: STAR(\*)D measurement-based care. *Neuropsychopharmacology* 2007; 32:2479–2489.
190. Nierenberg AA, Farabaugh AH, Alpert JE, Gordon J, Worthington JJ, Rosenbaum JF, Fava M: Timing of onset of antidepressant response with fluoxetine treatment. *Am J Psychiatry* 2000; 157:1423–1428.
191. Fava M, Thase ME, DeBattista C. A multicenter, placebo-controlled study of modafinil augmentation in partial responders to selective serotonin reuptake inhibitors with persistent fatigue and sleepiness. *J Clin Psychiatry* 2005;66:85-93.
192. Sharma V, Khan M, Smith A. A closer look at treatment resistant depression: is it due to a bipolar diathesis? *J of Affective Disorders* 2005;84:251-57.



ΕΥΡΩΠΑΪΚΗ ΕΝΩΣΗ



[www.ygeia-pronoia.gr](http://www.ygeia-pronoia.gr)

Με την συγχρηματοδότηση  
της Ελλάδας και της  
Ευρωπαϊκής Ένωσης



www.espa.gr

193. Trivedi MH, Fava M, Wisniewski SR, Thase ME, Quitkin F, Warden D, Ritz L, Nierenberg AA, Lebowitz BD, Biggs MM, Luther JF, Shores-Wilson K, Rush AJ: Medication augmentation after the failure of SSRIs for depression. *N Engl J Med* 2006; 354:1243–1252.
194. Thase ME, Friedman ES, Biggs MM, et al. Cognitive therapy versus medication in augmentation and switch strategies as second-step treatments: a STAR\*D report. *Am J Psychiatry* 2007;164:739-52.
195. McGrath PJ, Stewart JW, Nunes EV, et al. A double-blind crossover trial of imipramine and phenelzine for outpatients with treatment-refractory depression. *Am J Psychiatry* 1993;150:118-23.
196. Djernes JK: Prevalence and predictors of depression in populations of elderly: a review. *Acta Psychiatr Scand* 2006; 113:372–387.
197. Krishnan KR, DeLong M, Kraemer H, Carney R, Spiegel D, Gordon C, McDonald W, Dew M, Alexopoulos G, Buckwalter K, Cohen PD, Evans D, Kaufmann PG, Olin J, Otey E, Waincott C: Comorbidity of depression with other medical diseases in the elderly. *Biol Psychiatry* 2002; 52:559–588
198. Birrer RB, Vemuri SP. Depression in later life: a diagnostic and therapeutic challenge. *Am Fam Phys* 2004;69:2375-82
199. Dew MA, Whyte EM, Lenze EJ, Houck PR, Mulsant BH, Pollock BG, Stack JA, Bensasi S, Reynolds CF III: Recovery from major depression in older adults receiving augmentation of antidepressant pharmacotherapy. *Am J Psychiatry* 2007; 164:892–89.
200. Mandelli L, Serretti A, Zanardi R, Rossini D, De Ronchi D, Tarricone I, Colombo C: Antidepressant response in the elderly. *Psychiatry Res* 2007; 152:37–44.
201. Driscoll HC, Karp JF, Dew MA, Reynolds CF III: Getting better, getting well: understanding and managing partial and non-response to pharmacological treatment of non-psychotic major depression in old age. *Drugs Aging* 2007; 24:801–814.
202. Sheikh JI, Cassidy EL, Doraiswamy PM, Salomon RM, Hornig M, Holland PJ, Mandel FS, Clary CM, Burt T: Efficacy, safety, and tolerability of sertraline in patients with late-life depression and comorbid medical illness. *J Am Geriatr Soc* 2004; 52:86–9252:559–588.
203. Mottram P, Wilson K, Strobl J: Antidepressants for depressed elderly. *Cochrane Database Syst Rev* 2006; CD003491.



ΕΥΡΩΠΑΪΚΗ ΕΝΩΣΗ



[www.ygeia-pronoia.gr](http://www.ygeia-pronoia.gr)

Με την συγχρηματοδότηση  
της Ελλάδας και της  
Ευρωπαϊκής Ένωσης



Ε.Π.  
ΔΙΟΙΚΗΤΙΚΗ  
ΜΕΤΑΡΡΥΘΜΙΣΗ  
ΜΕΛΕΤΗ



ΕΣΠΑ  
2007-2013  
Πρόγραμμα για την ανάπτυξη  
ΕΥΡΩΠΑΪΚΟ ΚΟΙΝΩΝΙΚΟ ΤΑΜΕΙΟ

[www.espa.gr](http://www.espa.gr)

204. Gerson S, Belin TR, Kaufman A, Mintz J, Jarvik L: Pharmacological and psychological treatments for depressed older patients: a meta-analysis and overview of recent findings. *Harv Rev Psychiatry* 1999; 7:1–28.
205. Nelson JC, Delucchi K, Schneider LS: Efficacy of second generation antidepressants in late-life depression: a meta-analysis of the evidence. *Am J Geriatr Psychiatry* 2008; 16:558–567.
206. Serfaty. Marc Antony, Haworth Deborah, Blanchard Martin, Buszewicz Marta, Murad Shahed, King Michael, Clinical Effectiveness of Individual Cognitive Behavioral Therapy for Depressed Older People in Primary Care A Randomized Controlled Trial. *Arch Gen Psychiatry*. 2009;66(12):1332-1340.
207. . Hunkeler EM, Katon W, Tang L, et al. Long term outcomes from the IMPACT randomised trial for depressed elderly patients in primary care. *BMJ* 2006;332:259-63.
208. Benton T, Staab J, Evans DL. Medical comorbidity in depressive disorders. *Ann Clin Psychiatry*. 2007;19:289-303.
209. Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR\*D: implications for clinical practice. *Am J Psychiatry* 2006b;163:28-40.
210. Lépine JP, Briley M. The epidemiology of pain in depression. *Hum Psychopharmacol Clin Exp* 2004;19:S3-S7.
211. Husain MM, Rush AJ, Trivedi MH, et al. Pain in depression: STAR\*D study findings. *J Psychosomatic Research* 2007;63:113-22.
212. Bair MJ, Robinson RL, Katon W, Kroenke K. Depression and pain comorbidity. *Arch Intern Med* 2003;163: 2433-45.
213. Ali S, et al. The prevalence of co-morbid depression in adults with Type 2 diabetes: a systematic review and meta-analysis. *Diabetic Medicine*. 2006; 23(11):1165–1173.
214. [Roy T](#), [Lloyd CE](#). Epidemiology of depression and diabetes: a systematic review [J Affect Disord](#). 2012 Oct;142 Suppl:S8-21. doi: 10.1016/S0165-0327(12)70004-6.
215. Pirl WF. Evidence report on the occurrence, assessment, and treatment of depression in cancer patients. *J Natl Cancer Inst Monogr* 2004;32:32-39
216. Lo C, Zimmermann C, Rydall A, et al. Longitudinal study of depressive symptoms in patients with metastatic gastrointestinal and lung cancer. *J Clin Oncol*. 2010;28:3084-3089.



ΕΥΡΩΠΑΪΚΗ ΕΝΩΣΗ



[www.ygeia-pronoia.gr](http://www.ygeia-pronoia.gr)

Με την συγχρηματοδότηση  
της Ελλάδας και της  
Ευρωπαϊκής Ένωσης

2007-2013

Ε.Π.  
ΔΙΟΙΚΗΤΙΚΗ  
ΜΕΤΑΡΡΥΘΜΙΣΗ  
ΜΕΛΕΤΑΔΩΜΙΣΗ



www.espa.gr

217. Atkinson JH, Heaton RK, Patterson TL, et al. Two-year prospective study of major depressive disorder in HIV-infected men. *J Affect Disord.*2008;108:225-234.
218. Markowitz JC, Kocsis JH, Fishman B, et al. Treatment of depressive symptoms in human immunodeficiency virus-positive patients. *Arch Gen Psychiatry.*1998;55:452-457.
219. Ferrando SJ, Goldman JD, Charness WE. Selective serotonin reuptake inhibitor treatment of depression in symptomatic HIV infection and AIDS. Improvements in affective and somatic symptoms. *Gen Hosp Psych.* 1997;19:89-97.
220. Yun LW, Maravi M, Kobayashi JS, et al. Antidepressant treatment improves adherence to antiretroviral therapy among depressed HIV-infected patients. *J Acquir Immune Defic Syndr.* 2005;38:432-438.
221. [Menza M](#), [Dobkin RD](#), [Marin H](#). Treatment of depression in Parkinson's disease [Curr Psychiatry Rep.](#) 2006 Jun;8(3):234-40.
222. Thombs BD, Bass EB, Ford DE, et al. Prevalence of depression in survivors of acute myocardial infarction. *J Gen Intern Med.*2006;21:30-38.
223. Rudisch B, Nemeroff CB. Epidemiology of comorbid coronary artery disease and depression. *Biol Psychiatry.* 2003;54:227-240.
224. Thomas AJ, Kalaria RN, O'Brien JT. Depression and vascular disease: what is the relationship? *J Affect Disord.*2004;79:81-95.
225. Ramasubbu R. Relationship between depression and cerebrovascular disease: conceptual issues. *J Affect Disord.*2000;57:1-11.
226. Ciechanowski PS, Katon WJ, Russo JE. Depression and diabetes: impact of depressive symptoms on adherence, function, and costs. *Arch Intern Med* 2000;160:3278-85.
227. Pommer Antoinette M, Pouwer François Denollet, Johan, Pop Victor JM.. Managing co-morbid depression and anxiety in primary care patients with asthma and/or chronic obstructive pulmonary disease: study protocol for a randomized controlled trial. *Trials* 2012, 13:6.
228. Wulsin LR, Singal BM. Do depressive symptoms increase the risk for the onset of coronary disease? A systematic quantitative review. *Psychosom Med* 2003;65:201-10
229. Rugulies R. Depression as a predictor for coronary heart disease: a review and meta-analysis. *Am J Prev Med* 2002;23:51-61.



ΕΥΡΩΠΑΪΚΗ ΕΝΩΣΗ



[www.ygeia-pronoia.gr](http://www.ygeia-pronoia.gr)

Με την συγχρηματοδότηση  
της Ελλάδας και της  
Ευρωπαϊκής Ένωσης



Ε.Π.  
ΔΙΟΙΚΗΤΙΚΗ  
ΜΕΤΑΡΡΥΘΜΙΣΗ  
ΜΕΛΕΤΗ



www.espa.gr

230. Lichtman JH, Bigger Jr JT, Blumenthal JA, et al. Depression and coronary heart disease: recommendations for screening, referral, and treatment: a science advisory from the American heart association prevention committee of the council on cardiovascular nursing, council on clinical cardiology, council on epidemiology and prevention, and interdisciplinary council on quality of care and outcomes research: endorsed by the American psychiatric association. *Circulation* 2008;118:1768-75.
231. Nicholson A, Kuper H, Hemingway H. Depression as an aetiologic and prognostic factor in coronary heart disease: a meta-analysis of 6,362 events among 146,538 participants in 54 observational studies. *Eur Heart J* 2006;27:2763-74.
232. Jiang W, Davidson JRT. Antidepressant therapy in patients with ischemic heart disease. *Am Heart J* 2005;150:871-81.
233. Blumenthal JA, Lett HS, Babyak MA, et al. Depression as a risk factor for mortality after coronary artery bypass surgery. *Lancet* 2003;362:604-09.
234. Ballenger JC, Davidson JRT, Lecrubier Y, et al. Consensus statement on depression, anxiety, and cardiovascular disease. *J Clin Psychiatry* 2001;62:24-27.
235. The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and select comorbid medical conditions. *Annals of clinical psychiatry* 2012;24(1):91-109.
236. Kroenke Kurt, Bair Matthew J., Damush Teresa M, Wu Jingwei, Hoke Shawn, Sutherland Jason, Tu Wanzhu. Optimized Antidepressant Therapy and Pain Self-management in Primary Care Patients With Depression and Musculoskeletal Pain A Randomized Controlled Trial. *JAMA*. 2009;301(20):2099-2110
237. Mijung Park, Wayne J. Katon, Fredric M. Wolf. Depression and Risk of Mortality in Individuals with Diabetes: A Meta-Analysis and Systematic Review. *Gen Hosp Psychiatry*. 2013 ; 35(3): 217–225
238. Bogner Hillary R, Morales Knashawn H, De Vries Heather F, Cappola Anne R.. Integrated management of type 2 diabetes mellitus and depression treatment to improve medication adherence: A Randomized Controlled Trial. *Ann Fam Med* 2012;10:15-22. doi:10.1370/afm.1344.
239. Zimmerman M, Chelminski I, McDermut W: Major depressive disorder and Axis I diagnostic comorbidity. *J Clin Psychiatry* 2002; 63:187–193.





Με την συγχρηματοδότηση  
της Ελλάδας και της  
Ευρωπαϊκής Ένωσης



[www.ygeia-pronoia.gr](http://www.ygeia-pronoia.gr)

240. Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE: Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. *Arch Gen Psychiatry* 2005; 62:617–627.
241. Schatzberg AF, Ballenger JC: Decisions for the clinician in the treatment of panic disorder: when to treat, which treatment to use, and how long to treat. *J Clin Psychiatry* 1991; 52(suppl):26–31.
242. Schneier FR, Blanco C, Campeas R, Lewis-Fernandez R, Lin SH, Marshall R, Schmidt AB, Sanchez-Lacay JA, Simpson HB, Liebowitz MR: Citalopram treatment of social anxiety disorder with comorbid major depression. *Depress Anxiety* 2003; 17:191–196 52(suppl):26–3139.
243. American Psychiatric Association: Practice Guidelines for the Treatment of Patients With Panic Disorder, Second Edition. *Am J Psychiatry* 2009; 166:(Jan suppl)1–68.
244. Ninan PT, Rush AJ, Crits-Christoph P, Kornstein SG, Manber R, Thase ME, Trivedi MH, Rothbaum BO, Zajecka J, Borian FE, Keller MB: Symptomatic and syndromal anxiety in chronic forms of major depression: effect of nefazodone, cognitive behavioral analysis system of psychotherapy, and their combination. *J Clin Psychiatry* 2002; 63:434–44.
245. Pavey TG, Taylor AH, Fox KR, Hillsdon M, Anokye N, Campbell JL, Foster C, Green C, Moxham T, Mutrie N, Searle J, Trueman P, Taylor RS. [Effect of exercise referral schemes in primary care on physical activity and improving health outcomes: systematic review and meta-analysis BMJ 2011;343:d6462 doi: 10.1136/bmj.d6462.](https://doi.org/10.1136/bmj.d6462)
246. Blumenthal JA, Babyak MA, Doraiswamy PM, Watkins L, Hoffman BM, Barbour KA, et al. Exercise and pharmacotherapy in the treatment of major depressive disorder. *Psychosom Med* 2007;69(7):587-96.
247. Blumenthal JA, Babyak MA, Moore KA, Craighead WE, Herman S, Khatri P, et al. Effects of exercise training on older patients with major depression. *Arch Intern Med* 1999;159(19):2349-56.
- 3.
248. Dunn AL, Trivedi MH, Kampert JB, Clark CG, Chambliss HO. The DOSE study: a clinical trial to examine efficacy and dose response of exercise as treatment for depression. *Control Clin Trials* 2002;23(5):584-603.
249. Dunn AL, Madhukar HT, Kampert JB, et al. Exercise treatment for depression: efficacy and dose response. *Am J Prev Med* 2005;28:1-8.



ΕΥΡΩΠΑΪΚΗ ΕΝΩΣΗ



[www.ygeia-pronoia.gr](http://www.ygeia-pronoia.gr)

Με την συγχρηματοδότηση  
της Ελλάδας και της  
Ευρωπαϊκής Ένωσης



www.espa.gr

250. Mather AS, Rodriguez C, Guthrie MF, McHarg AM, Reid IC, McMurdo ME. Effects of exercise on depressive symptoms in older adults with poorly responsive depressive disorder: randomised controlled trial. *Br J Psychiatry* 2002;180: 411-5.
251. Nabkasorn C, Miyai N, Sootmongkol A, Junprasert S, Yamamoto H, Arita M, et al. Effects of physical exercise on depression, neuroendocrine stress hormones and physiological fitness in adolescent females with depressive symptoms. *Eur J Public Health* 2006;16(2):179-84.
252. Singh NA, Clements KM, Singh MA. The efficacy of exercise as a long-term antidepressant in elderly subjects: a randomized, controlled trial. *J Gerontol A Biol Sci Med Sci* 2001;56(8):M497-504.
253. Babyak M, Blumenthal JA, Herman S, et al. Exercise treatment for major depression: maintenance of therapeutic benefit at 10 months. *Psychosom Med* 2000;62:633-38.
254. Schuch FB, Vasconcelos-Moreno MP, Borowsky C, Fleck MP. Exercise and severe depression: preliminary results of an add-on study. *J Affect Disord* 2011;133:615-18.
255. [Cooney GM](#), [Dwan K](#), [Greig CA](#), [Lawlor DA](#), [Rimer J](#), [Waugh FR](#), [McMurdo M](#), [Mead GE](#). Exercise for depression. *Cochrane Database Syst Rev*. 2013 Sep 12;9:CD004366. doi: 10.1002/14651858.CD004366.pub6.
256. Josefsson T, Lindwall M, Archer T. Physical exercise intervention in depressive disorders: meta-analysis and systematic review. *Scand J Med Sci Sports*. 2014 Apr;24(2):259-72. doi: 10.1111/sms.12050. Epub 2013 Jan 30.
257. Gemma Taylor, Ann McNeill, Alan Girling, Amanda Farle, Nicola Lindson-Hawley, Paul Aveyard. Change in mental health after smoking cessation: systematic review and meta-analysis. *BMJ* 2014;348:g1151 doi: 10.1136/bmj.g1151
258. Katon, W. J., Lin, E. H.B., Korff, M. V., Ciechanowski, P., Ludman, E. J., Young, B., Peterson, D., Rutter, C. M., McGregor M. and McCulloch, D. Collaborative Care for Patients with Depression and Chronic Illnesses. *The New England Journal of Medicine* 2010; 363(27):2611-2620.
259. Sherbourne CD, Hays RD, Ordway L, DiMatteo MR, Kravitz RL. Antecedents of adherence to medical recommendations: results from the Medical Outcomes Study. *J Behav Med* 1992;15:447-68.
- 260.. Wagner EH, Austin BT, Von Korff M. Organizing care for patients with chronic illness. *Milbank Q* 1996;74:511-44.
261. Southard EP, Neufeld JD, Laws S. Telemental Health Evaluations Enhance Access and Efficiency in a Critical Access Hospital Emergency Department. *Telemed J E Health*. 2014 May 8.



ΕΥΡΩΠΑΪΚΗ ΕΝΩΣΗ



[www.ygeia-pronoia.gr](http://www.ygeia-pronoia.gr)

Με την συγχρηματοδότηση  
της Ελλάδας και της  
Ευρωπαϊκής Ένωσης



Ε.Π.  
ΔΙΟΙΚΗΤΙΚΗ  
ΜΕΤΑΡΡΥΘΜΙΣΗ  
ΜΕΛΕΤΑΔΕΙΞΗ



www.espa.gr

262. Seidel RW, Kilgus MD Agreement between telepsychiatry assessment and face-to-face assessment for Emergency Department psychiatry patients. J Telemed Telecare. 2014 Mar;20(2):59-62.

## Παράρτημα 1: Γλωσσάριο

Π.Φ.Υ.	Πρωτοβάθμια Φροντίδα Υγείας
Π.Ο.Υ.	Παγκόσμιος Οργανισμός Υγείας
Κ.Ο.	Κατευθυντήρια Οδηγία
ΜΚΔ	Μείζονα Καταθλιπτική Διαταραχή
ΤΕΚΔ	Τυχαιοποιημένη Ελεγχόμενη Κλινική Δοκιμή
ΓΣΘ	Γνωστική Συμπεριφορική Θεραπεία



ΕΥΡΩΠΑΪΚΗ ΕΝΩΣΗ



ΥΠΟΥΡΓΕΙΟ ΥΓΕΙΑΣ

Με την συγχρηματοδότηση  
της Ελλάδας και της  
Ευρωπαϊκής Ένωσης



Ε.Π.  
ΔΙΟΙΚΗΤΙΚΗ  
ΜΕΤΑΡΡΥΘΜΙΣΗ  
ΜΕΣΤΡΩΣΕΩΝ



ΕΥΡΩΠΑΪΚΟ ΚΟΙΝΩΝΙΚΟ ΤΑΜΕΙΟ

www.espa.gr

[www.ygeia-pronoia.gr](http://www.ygeia-pronoia.gr)

"Αυτό το έγγραφο έχει παραχθεί για τις ανάγκες του έργου με τίτλο «Ανάπτυξη 13 Κατευθυντήριων Οδηγιών Γενικής Ιατρικής για τη διαχείριση των πιο συχνών νοσημάτων και καταστάσεων υγείας στην Πρωτοβάθμια Φροντίδα Υγείας» και αντιπροσωπεύει τις απόψεις των συντακτών του. Οι απόψεις αυτές δεν έχουν υιοθετηθεί ή εγκριθεί με οποιοδήποτε τρόπο από την Ειδική Υπηρεσία του τομέα Υγείας & Κοινωνικής Αλληλεγγύης και της Ευρωπαϊκής Επιτροπής και δεν πρέπει να εκλαμβάνονται ως θέσεις του Υπουργείου ή της Επιτροπής. Η Ειδική Υπηρεσία δεν εγγυάται την ακρίβεια των στοιχείων που περιλαμβάνονται στο παρόν έγγραφο, ούτε αποδέχεται την ευθύνη για οποιαδήποτε χρήση των πληροφοριών αυτών. "